Research Progress on the Combination Therapy of EGFR-TKIs and Metformin
in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2023.106.22
- Author:
Jiamin WANG
1
;
Pan LIU
2
;
Lisha YING
2
;
Rui ZHU
2
;
Chaodan YANG
1
;
Ying YANG
3
;
Dan SU
1
Author Information
1. School of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
2. Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou 310022, China.
3. The Second Clinical Medical College, Zhejiang Chinese Medicine University, Hangzhou 310053, China.
- Publication Type:Journal Article
- Keywords:
Combined therapy;
Epidermal growth factor receptor-tyrosine kinase inhibitors;
Lung neoplasms;
Metformin;
Targeted therapy
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/genetics*;
Lung Neoplasms/genetics*;
Metformin/therapeutic use*;
Protein Kinase Inhibitors/therapeutic use*;
ErbB Receptors/metabolism*;
Drug Resistance, Neoplasm;
Mutation
- From:
Chinese Journal of Lung Cancer
2023;26(11):874-880
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) targeting EGFR are effective in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients, but drug resistance is inevitable. With the application and expansion of individualized and combined therapy, more and more studies have shown that combined administration of Metformin effectively solves the problem of acquired drug resistance to EGFR-TKIs in clinical treatment and prolongs the survival of patients with NSCLC. EGFR-TKIs combined with Metformin is expected to be the treatment method of choice for NSCLC patients with EGFR-TKIs resistance. This paper intends to summarize the research progress of EGFR-TKIs combined with Metformin in the treatment of EGFR-TKIs acquired resistance in NSCLC, in order to provide a new idea for the treatment of NSCLC patients with acquired resistance to EGFR-TKIs.
.
